A method for the production of CD4+ chronic myelogenous leukemia- specific allogeneic T lymphocytes

Cancer Research

Volumn 57, Issue 8, 1997, Pages 1547-1553

  Serody, Jonathan S ^a   Brecher, Mark E ^a   Dent, Georgette ^a   Bentley, Stuart A ^a   Frelinger, Jeffrey A ^a   Shea, Thomas C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD4 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 7;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; LYMPHOCYTOPOIESIS; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0030907467     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Miller, J. S., and McGlave, P. B. Therapy for chronic myelogenous leukemia with marrow transplantation. Curr. Opin. Oncol., 5: 262-269, 1993.
2. Snyder, D. S., Negrin, R. S., O'Donnell, O. D. M. R., Chao, N. J., Amylon, M. D., Long, G. D., Nademanee, A. P., Stein, A. S., Parker, P. M., Smith, E. P., Somlo, G., Margolin, K., Molina, A., Stepan, D. E., Lipsett, J. A., Hoppe, R. T., Slovak, M. L., Niland, J. C., Dagis, A. C., Wong, R. M., Forman, S. J., and Blume, K. G. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood, 84: 1672-1679, 1994.
3. Martin, P. J., Hansen, J. A., Buckner, C. D., Sanders, J. E., Deeg, H. J., Stewart, P., Appelbaum, F. R., Clift, R., Fefer, A., Witherspoon, R. P., Kennedy, M. S., Sullivan, K. M., Flournoy, N., Storb, R., and Thomas, E. D. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood, 66: 664-672, 1985.
4. Slavin, S., Ackerstein, A., Naparstek, E., Or, R., and Weiss, L. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant., 6: 155-161, 1990.
5. Drobyski, W. R., Ash, R. C., Casper, J. T., McAuliffe, T., Horowitz, M. M., Lawton, C., Keever, C., Baxter-Lowe, L. A., Camitta, B., Garbrecht, F., Pietryga, D., Hansen, R., Chitambar, C. R., Anderson, T., and Flomenberg, N. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood, 83: 1980-1987, 1994.
6. Kolb, H. J., Schattenberg, A., Goldman, J. M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E., and Ansari, H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86: 2041-2050, 1995.
7. Drobyski, W. R., Keever, C. A., Roth, M. S., Koethe, S., Hanson, G., McFadden, P., Gottschall, J. L., Ash, R. C., van Tuinen, P., Horowitz, M. M., and Flomenberg, N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood, 82: 2310-2318, 1993.
8. Porter, D. L., Roth, M. S., McGarigle, C., Ferrara, J. L., and Antin, J. H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330: 100-106, 1994.
9. Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Kapelushnik, J., and Or, R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp. Hematol. (NY), 23: 1553-1562, 1995.
10. van Rhee, F., Lin, F., Cullis, J. O., Spencer, A., Cross, N. C., Chase, A., Garicochea, B., Bungey, J., Barrett, J., and Goldman, J. M. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood, 83: 3377-3383, 1994.
11. Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H., Reich, L., Collins, N. H., Boulad, F., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., Kernan, N. A., Small, T. N., Young, J. W., and O'Reilly, R. J. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86: 1261-1268, 1995.
12. Hercend, T., Takvorian, T., Nowill, A., Tantravahi, R., Moingeon, P., Anderson, K. C., Murray, C., Bohuon, C., Ythier, A., and Ritz, J. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood, 67: 722-728, 1986.
13. Faber, L. M., van der Hoeven, J., Goulmy, E., Hooftman-den Otter, A. L., van Luxemburg-Heijs, S. A., Willemze, R., and Falkenburg, J. H. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Clin. Invest., 96: 877-883, 1995.
14. Champlin, R., Jansen, J., Ho, W., Gajewski, J., Nimer, S., Lee, K., Territo, M., Winston, D., Tricot, G., and Reichert, T. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant. Proc., 23: 1695-1696, 1991.
15. Colligan, J., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W. Current Protocols in Immunology. New York: John Wiley & Sons, Inc., 1994.
16. Kawasaki, E. S., Clark, S. S., Coyne, M. Y., Smith, S. D., Champlin, R., Witte, O. N., and McCormick, F. P. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc. Nail. Acad. Sci. USA, 85: 5698-5702, 1988.
17. Pogue, R. R., Eron, J., Frelinger, J. A., and Matsui, M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. USA, 92: 8166-8170, 1995.
18. Oettel, K. R., Wesly, O. H., Albertini, M. R., Hank, J. A., Iliopolis, O., Sosman, J. A., Voelkerding, K., Wu, S. Q., Clark, S. S., and Sondel, P. M. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (PM+) human leukemia lines can also recognize Ph1- cells from the same patient. Blood. 83: 3390-3402, 1994.
19. Faber, L. M., van-Luxemburg-Heijs, S. A. P., Rijnbeek, M., Willemze, R., and Falkenburg, J. H. F. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of α-interferon. Biol. Blood & Marrow Transplant., 2: 31-36, 1996.
20. Chen, W., Peace, D. J., Rovira, D. K., You, S. G., and Cheever, M. A. T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. Sci. USA, 89: 1468-1472, 1992.
21. ten Bosch, G. J., Toornvliet, A. C., Friede, T., Melief, C. J., and Leeksma, O. C. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia (Baltimore), 9: 1344-1348, 1995.
22. Bocchia, M., Wentworth, P. A., Southwood, S., Sidney, J., McGraw, K., Scheinberg, D. A., and Sette, A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood, 85: 2680-2684, 1995.